The Toronto HCV protocol prevented or rapidly cleared HCV infection in D+R– recipients of non-liver solid organ transplants, with no difference in overall survival versus matched D−R− controls. This s...

The trial did not show a clinical benefit of faecal microbiota transplantation in patients with IBS. These findings suggest that microbiota modulation alone might be insufficient for symptom improveme...

EO-CRC represents a rapidly expanding burden in EMRO, characterised by high and inequitable cancer mortality, substantial inter-country heterogeneity in both EO-CRC incidence and mortality, and marked...

Hepatocellular carcinoma (HCC) is an increasing and evolving health challenge in Europe, shaped by changing liver disease epidemiology, persistent gaps in surveillance, and rapid advances in treatment...

Liver fibrosis and steatotic liver disease are prevalent in community-dwelling Chinese adults, driven by metabolic factors and alcohol consumption. These findings identify chronic liver disease as a m...

SUSD1 is a risk locus for renal impairment in decompensated cirrhosis, with genetic effects that appear context-dependent across cirrhosis stages and the general population. Our findings implicate the...

Early top-down anti-TNF treatment from diagnosis was associated with improved long-term outcomes at 5 years compared with step-up treatment and is suggestive of a disease-modifying effect in Crohn's disease.

Statistically significant reductions in liver fat with ALG-055009 and no relevant safety issues suggest that ALG-055009 could offer a promising treatment approach for patients with MASH. Results suppo...

On-demand TACE plus atezolizumab and bevacizumab significantly improved TACE-PFS versus on-demand TACE alone. Overall survival follow-up is ongoing.

The epidemiology of inflammatory bowel disease (IBD) progresses through four stages: emergence (stage 1), acceleration in incidence (stage 2), compounding prevalence (stage 3), and prevalence equilibr...

In this prespecified 12-week primary analysis, DD01 produced rapid reductions in liver fat compared with placebo, supporting further evaluation in long-term studies.

CADe-assisted colonoscopy did not show the absolute improvement in adenoma detection rate that was assumed in the prespecified sample-size calculation. CADx did not clearly improve lesion differentiat...

Duvakitug showed significant evidence for clinical remission versus placebo, with no safety concerns identified, in patients with moderately to severely active ulcerative colitis.

In participants with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, the combination of zalfermin 30 mg plus semaglutide 2·4 mg did not significantly increase the...

LGIB in older adults presents distinct clinical features with more severe bleeding. Higher baseline vulnerability might explain the age-related differences in escalation of care and worse outcomes. Th...

Although non-inferiority could not formally be concluded for either 100 mg or 300 mg of aspirin daily by comparison with 600 mg aspirin daily, there was evidence that the 100 mg dose had similar chara...

Phase 2 trial shows dupilumab improves key measures of disease activity in eosinophilic gastritis, a rare inflammatory stomach condition.

The improvement of histological outcomes of eosinophilic gastritis with dupilumab in this proof-of-concept study shows type 2 inflammatory involvement in the disease and the potential value of dupilum...

The addition of ipilimumab to atezolizumab plus bevacizumab did not show any benefit in patients with previously untreated, unresectable hepatocellular carcinoma. These results do not support the addi...